Telatinib in Combination With Capecitabine/ Oxaliplatin in 1st Line Gastric or GEJ Cancer
Status:
Unknown status
Trial end date:
2021-01-25
Target enrollment:
Participant gender:
Summary
The purpose of the trial is to compare the combination regimen of Telatinib and Capecitabine
and Oxaliplatin vs. Capecitabine and Oxaplatin to explore superiority of the Telatinib
combination in terms of progression-free survival (PFS) in patients previously untreated for
advanced HER2 negative advanced gastric or Gastroesophageal Junction adenocarcinoma.